3D Printing of Pediatric Medication: The End of Bad Tasting Oral Liquids?-A Scoping Review
- PMID: 35214148
- PMCID: PMC8880000
- DOI: 10.3390/pharmaceutics14020416
3D Printing of Pediatric Medication: The End of Bad Tasting Oral Liquids?-A Scoping Review
Abstract
3D printing of pediatric-centered drug formulations can provide suitable alternatives to current treatment options, though further research is still warranted for successful clinical implementation of these innovative drug products. Extensive research has been conducted on the compliance of 3D-printed drug products to a pediatric quality target product profile. The 3D-printed tablets were of particular interest in providing superior dosing and release profile similarity compared to conventional drug manipulation and compounding methods, such as oral liquids. In the future, acceptance of 3D-printed tablets in the pediatric patient population might be better than current treatments due to improved palatability. Further research should focus on expanding clinical knowledge, providing regulatory guidance and expansion of the product range, including dosage form possibilities. Moreover, it should enable the use of diverse good manufacturing practice (GMP)-ready 3D printing techniques for the production of various drug products for the pediatric patient population.
Keywords: 3D printing; compounded drug formulations; drug formulation development; pediatrics; personalized medicine; pharmaceutical technology.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
The potential of three-dimensional printing for pediatric oral solid dosage forms.Acta Pharm. 2024 May 30;74(2):229-248. doi: 10.2478/acph-2024-0012. Print 2024 Jun 1. Acta Pharm. 2024. PMID: 38815205 Review.
-
3D printed extended release tablets for once daily use: An in vitro and in vivo evaluation study for a personalized solid dosage form.Int J Pharm. 2021 Mar 1;596:120222. doi: 10.1016/j.ijpharm.2021.120222. Epub 2021 Jan 21. Int J Pharm. 2021. PMID: 33484916
-
Development of immediate release (IR) 3D-printed oral dosage forms with focus on industrial relevance.Eur J Pharm Sci. 2020 Dec 1;155:105558. doi: 10.1016/j.ejps.2020.105558. Epub 2020 Sep 16. Eur J Pharm Sci. 2020. PMID: 32946957
-
3D-Printed Isoniazid Tablets for the Treatment and Prevention of Tuberculosis-Personalized Dosing and Drug Release.AAPS PharmSciTech. 2019 Jan 7;20(2):52. doi: 10.1208/s12249-018-1233-7. AAPS PharmSciTech. 2019. PMID: 30617660 Free PMC article.
-
3D-Printed Oral Dosage Forms: Mechanical Properties, Computational Approaches and Applications.Pharmaceutics. 2021 Sep 3;13(9):1401. doi: 10.3390/pharmaceutics13091401. Pharmaceutics. 2021. PMID: 34575475 Free PMC article. Review.
Cited by
-
Novel Approach to Pharmaceutical 3D-Printing Omitting the Need for Filament-Investigation of Materials, Process, and Product Characteristics.Pharmaceutics. 2022 Nov 17;14(11):2488. doi: 10.3390/pharmaceutics14112488. Pharmaceutics. 2022. PMID: 36432679 Free PMC article.
-
Assessment of a Semi-solid Extrusion Based Compounding System Solution for Personalized Ondansetron Dosage Forms Combined with Raman Spectroscopy Analysis.Pharm Res. 2025 Aug 19. doi: 10.1007/s11095-025-03911-6. Online ahead of print. Pharm Res. 2025. PMID: 40830727
-
Development of Personalised Immediate-Release Gel-Based Formulations Using Semi-Solid Extrusion.Gels. 2024 Oct 17;10(10):665. doi: 10.3390/gels10100665. Gels. 2024. PMID: 39451318 Free PMC article.
-
Innovations in Chewable Formulations: The Novelty and Applications of 3D Printing in Drug Product Design.Pharmaceutics. 2022 Aug 18;14(8):1732. doi: 10.3390/pharmaceutics14081732. Pharmaceutics. 2022. PMID: 36015355 Free PMC article. Review.
-
Development of 3D-Printed Chewable Gummy Tablets with Adjustable Ondansetron Content for the Treatment of Pediatric Patients.Pharmaceutics. 2025 Apr 2;17(4):458. doi: 10.3390/pharmaceutics17040458. Pharmaceutics. 2025. PMID: 40284453 Free PMC article.
References
-
- Walsh J., Schaufelberger D., Iurian S., Klein S., Batchelor H., Turner R., Gizurarson S., Boltri L., Alessandrini E., Tuleu C. Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a c4c expert group White paper. Br. J. Clin. Pharmacol. 2021:1–18. doi: 10.1111/bcp.14989. - DOI - PubMed
-
- COMMISSION STAFF WORKING DOCUMENT EVALUATION Joint Evaluation of Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use and Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. SWD/2020/163 Final. [(accessed on 10 November 2021)]. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A52020SC0163.
-
- Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA Relevance). OJ L 378, 27.12.2006, 1–19. [(accessed on 10 November 2021)]. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32006R1901.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials